for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shilpa Medicare Ltd

SHME.NS

Latest Trade

266.65INR

Change

6.75(+2.60%)

Volume

13,822

Today's Range

256.00

 - 

271.00

52 Week Range

208.10

 - 

435.05

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
259.90
Open
260.80
Volume
13,822
3M AVG Volume
0.48
Today's High
271.00
Today's Low
256.00
52 Week High
435.05
52 Week Low
208.10
Shares Out (MIL)
81.53
Market Cap (MIL)
21,188.84
Forward P/E
17.80
Dividend (Yield %)
0.38

Next Event

Q2 2020 Shilpa Medicare Ltd Earnings Release

Latest Developments

More

India's Shilpa Medicare Sets Final Dividend Of 1 Rupee Per Share

India's Shilpa Medicare June-Qtr Consol Net Profit Drops

Shilpa Medicare's Raichur Site Gets U.S. FDA Form 483 With 5 Observations

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shilpa Medicare Ltd

Shilpa Medicare Limited is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates, and wind power generation. The Company's segments include Bulk Drug/Intermediates and Energy. It offers 3a 7b Dihydroxy. The Company deals with APIs, Intermediates, Formulations, New Drug Delivery Systems, Peptides/Biotech products and Specialty Chemicals. The Company supplies oncology/non-oncology APIs and intermediates. Its oncology API products include Anastrozole, Axitinib, Azacitidine, Abiraterone Acetate, Bicalutamide, Bortezomib, Busulphan, Cabazitaxel Amorphous, Capecitabine, Carboplatin, Cladribine, Clofarabine, Zoledronic acid, Vismodegib, Pemetrexed DiPotassium Nonahydrate, Cyclophosphamide Monohydrate and Cytarabine. It also offers AntiRetroVirals. Its non-oncology API products include Acebrophylline, Echothiophate, Nifedipine, Perfenidone, PrucaloprideSuccinate, Sildenafil Citrate, Ursodeoxycholic acid and Dimethyl Fumarate.

Industry

Biotechnology & Drugs

Contact Info

#12-6-214/A1,, Hyderabad Road,

+91.8532.238704

http://www.vbshilpa.com/

Executive Leadership

Omprakash Inani

Non-Executive Chairman of the Board

Sushil Bajaj

Chief Financial Officer, Compliance Officer

Vishnukant C. Bhutada

Managing Director, Executive Director

Pramod Badrinarayan Kasat

Non-Executive Independent Director

Rajendra Sunki Reddy

Non-Executive Independent Director

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

7.8K

2018

7.9K

2019

7.3K

2020(E)

7.8K
EPS (INR)

2017

14.350

2018

13.200

2019

11.330

2020(E)

14.600
Price To Earnings (TTM)
22.71
Price To Sales (TTM)
3.04
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
15.84
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-India's Shilpa Medicare ‍Declared Interim Dividend Of 0.70 Rupees Per Shr

* DECLARED INTERIM DIVIDEND OF 0.70 RUPEES PER EQUITY SHARE Source text - http://bit.ly/2sKO9xj Further company coverage:

BRIEF-India's Shilpa Medicare Dec-Qtr Consol Profit Falls

* DEC QUARTER CONSOL PROFIT 163.4 MILLION RUPEES VERSUS PROFIT OF 170.5 MILLION RUPEES YEAR AGO

BRIEF-India's Shilpa Medicare Says U.S. FDA Issues 3 483 Observations To Co's Karnataka Units

* US FDA COMPLETED INSPECTION OF CO'S API FACILITIES UNIT-I AND UNIT-II LOCATED AT RAICHUR, KARNATAKA

BRIEF-Shilpa Medicare Gets 483 Observations From U.S. FDA For SEZ Formulation Facilities In Telangana

* SAYS GOT 483 OBSERVATIONS FROM U.S. FDA IN RELATION TO SEZ FORMULATION FACILITIES SITUATED AT JADCHERLA, TELANGANA

BRIEF-India's Shilpa Medicare Sept-qtr profit rises

* Sept quarter profit 481.9 million rupees versus 331.9 million rupees year ago

BRIEF-India's Shilpa Medicare says Rajendra Dugar resigns as CFO

* Says Rajendra Dugar resigns as CFO Source text - http://bit.ly/2z4zHTh Further company coverage:

BRIEF-India's Shilpa Medicare June-qtr profit rises

* June quarter profit 278.8 million rupees versus profit of 240.9 million rupees year ago

BRIEF-India cenbank says FIIs/FPIs can now invest 30-40 pct in Shilpa Medicare

* FIIs/FPIs can now invest 30 to 40 per cent under PIS in Shilpa Medicare Limited Source text - (http://bit.ly/2uyzCV4) Further company coverage:

BRIEF-India's Shilpa Medicare March-qtr profit rises

* March quarter profit 419.6 million rupees versus 339.9 million rupees year ago

BRIEF-Shilpa Medicare declares interim dividend of 0.60 rupees per share

* Says declared an interim dividend of INR 0.60 per equity share Source text:http://bit.ly/2m5xsF5 Further company coverage:

BRIEF-Shilpa Medicare declares interim dividend 0.60 rupees per share

* Says declared an interim dividend 0.60 rupees per share Source text: [We hereby intimate that the Board of Directors of the Company at their meeting held on 9th March, 2017 declared an Interim Dividend @ 60% i.e Re.0.60 (Sixty Paise) per equity share of Re.1/- each for...

BRIEF-Shilpa Medicare Dec-qtr profit falls

* Dec quarter net profit 273.5 million rupees versus profit 321.3 million rupees year ago

BRIEF-Shilpa Medicare to consider issue of equity shares or convertible securities

* Says to consider the issue of equity shares or convertible securities on preferential basis Source text: http://bit.ly/2gyIIqn Further company coverage:

BRIEF-Shilpa Medicare appoints Rajendra Dugar as CFO

* says appointed Rajendra Dugar as CFO Source text: (http://bit.ly/2gGwfFe) Further company coverage: (Bengaluru newsroom)

BRIEF-Shilpa Medicare says UK unit got marketing authorizations for cancer drug from UK MHRA

* UK unit got marketing authorizations from UK MHRA for the Imatinib tablets in multiple strengths of 100 mg and 400 mg.

BRIEF-Shilpa Medicare gets USFDA approval for Azacitidine injection

* Received an approval from the United States Food & Drug Administration for Azacitidine - Injection Anda of SEZ formulations facility situated at Jadcherla Source text: http://bit.ly/2doO3Sd Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up